Dianthus Therapeutics’ (DNTH) Buy Rating Reaffirmed at Guggenheim
Guggenheim reiterated their buy rating on shares of Dianthus Therapeutics (NASDAQ:DNTH – Free Report) in a research note released on Wednesday,Benzinga reports. They currently have a $84.00 price objective on the stock. Several other research firms have also recently commented on DNTH. HC Wainwright restated a “buy” rating and set a $40.00 price target on […]
Guggenheim reiterated their buy rating on shares of Dianthus Therapeutics (NASDAQ:DNTH – Free Report) in a research note released on Wednesday,Benzinga reports. They currently have a $84.00 price objective on the stock. Several other research firms have also recently commented on DNTH. HC Wainwright restated a “buy” rating and set a $40.00 price target on […]
